protein tyrosine phosphatase receptor type Z1Genealiases: HPTPZ · HPTPzeta · PTP-ZETA · PTP18 · PTPRZ · PTPZ
Q-omics provides the consensus-scored PTPRZ1 profile across patient tissues and cancer cell-line models. PTPRZ1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PTPRZ1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PTPRZ1 RNA expression shows 17,292 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where PTPRZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRZ1 survival associations across molecular data types. PTPRZ1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (12) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRZ1 RNA expression–survival associations across cancer types. High PTPRZ1 expression shows unfavorable associations in KIRP, SCLC, BLCA and UVM, but favorable associations in HNSC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PTPRZ1 RNA expression.
This table summarizes PTPRZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRZ1 shows lower tumor expression in COAD, KIRC, STAD and KIRP and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher PTPRZ1 RNA expression in tumor versus normal tissue (log2 FC = +1.608, t-test p < 0.001).
This table shows molecular features associated with PTPRZ1 in patient tissues and cancer cell lines. In patient samples, PTPRZ1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
